Prognostic Significance of HER2 Expression for Gastric Cancer With Clinically Para-aortic Lymph Node Metastasis.
Anticancer Res
; 41(6): 3099-3107, 2021 Jun.
Article
in En
| MEDLINE
| ID: mdl-34083303
ABSTRACT
BACKGROUND/AIM:
To determine the prognostic utility of trastuzumab-based chemotherapy based on human epidermal growth factor receptor 2 (HER2) expression in patients with para-aortic lymph node (PAN) metastasis from gastric cancer. PATIENTS ANDMETHODS:
A total of 41 patients with clinical PAN metastasis from gastric cancer who underwent chemotherapy were retrospectively enrolled.RESULTS:
Eighteen (43.9%) patients had HER2-positive tumors and consequently, received trastuzumab-based chemotherapy. A total of 11 patients underwent surgery. HER2 status was significantly correlated with the number of distant metastatic sites, the presence or absence of trastuzumab-based chemotherapy, and the presence or absence of gastrectomy. HER2-positive patients had significantly better prognosis than HER2-negative patients. Multivariate analysis identified age and trastuzumab-based chemotherapy based on HER2 status as an independent prognostic factor.CONCLUSION:
Assessing HER2 expression and subsequent trastuzumab-based chemotherapy can be an effective method for determining the prognosis of patients with PAN metastasis from gastric cancer.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Aorta
/
Stomach Neoplasms
/
Receptor, ErbB-2
/
Lymphatic Metastasis
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Anticancer Res
Year:
2021
Document type:
Article